AL-611 is a prodrug to a nucleoside inhibitor of HCV NS5B polymerase. While there have been very successful nucleoside drugs (e.g. sofosbuvir), several nucleoside inhibitors of HCV previously failed in the clinic due to severe toxicities, in some cases due to incorporation of the nucleosides into host RNA. The Janssen Biopharma (formerly [...]
< 1 minute read
Sep. 18, 2021
AL-611: An Oral HCV NS5B Polymerase Inhibitor Prodrug
AL-611
oral HCV NS5B polymerase inhibitor prodrug preclin.candidate, discont.Õd due to compet. from optimization of prior leads J. Med. Chem., Sep. 24, 2020 Janssen BioPharma, South San Francisco, CA
Loading...
